FDA Roundup: November 22, 2024
Written by Emily J. Thompson, Senior Investment Analyst
0mins
Source: Newsfilter
FDA Criminal Investigations: The FDA's Office of Criminal Investigations has successfully prosecuted a Dallas anesthesiologist for tampering with consumer products, resulting in a 190-year prison sentence, while also reminding food importers about new mycotoxin testing requirements starting December 1, 2024.
Medical Device and Drug Approvals: The FDA is enhancing its medical device recall communication process and granted accelerated approval for Jazz Pharmaceuticals' Ziihera for treating certain types of cancer, alongside updated guidance on third-party reviews for medical devices.
Analyst Views on JAZZ
Wall Street analysts forecast JAZZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAZZ is 218.92 USD with a low forecast of 188.00 USD and a high forecast of 263.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 171.000
Low
188.00
Averages
218.92
High
263.00
Current: 171.000
Low
188.00
Averages
218.92
High
263.00
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
